BOLD compared with NVCT: revenue, margins and what each company keeps, and the suppliers and customers both name

BOLDBoundless Bio, Inc.

Mkt capRevenueRevenue

NVCTNuvectis Pharma, Inc.

Mkt capRevenueRevenue

Compare

BOLDBoundless Bio, Inc.

NVCTNuvectis Pharma, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

BOLD

No earnings history for BOLD.

NVCT

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±38.9%▼−6.94%×0.18

Q1 FY26±56.7%▲+9.22%×0.16

Feb 11 '26±83.7%▲+0.46%×0.01

Nov 4 '25±52.7%▼−7.55%×0.14

= impliedBOLD realized, solidNVCT realized, hatchedOne scale, both sides: full bar = 84%× = |realized| ÷ impliedSource: market data

BOLDBoundless Bio, Inc.

2.45▼−1.21%· post 2.45

Mkt cap$56.2M

NVCTNuvectis Pharma, Inc.

18.38▼−1.00%· post 18.99

ClosedOct 30 '26

Mkt cap$602.1M

Compare

ClosedOct 30 '26

BOLDBoundless Bio, Inc.

NVCTNuvectis Pharma, Inc.

2.45▼−1.21%post 2.45

Price

18.38▼−1.00%post 18.99

$56.2M

Mkt cap

$602.1M

BOLD2.45▼−1.21%vsNVCT18.38▼−1.00%ClosedOct 30 '26